Browsing: NHIF Prostrate Cancer drug

www.theexchange.africa
  • Prostate cancer patients covered by the National Hospital Insurance Fund (NHIF) can now access an innovator prescription drug manufactured and distributed by Janssen Kenya
  • The prescription drug, Abiraterone Acetate used for the treatment of advanced prostate cancer will be made available to NHIF members within their existing benefits package
  • NHIF Chairperson Lewis Nguyai described the partnership as a landmark development that will help boost the local access to innovator drugs

Prostate cancer patients covered by the National Hospital Insurance Fund (NHIF) can now access an innovator prescription drug manufactured and distributed by Janssen Kenya, one of the pharmaceutical companies of Johnson & Johnson, as part of strategic development to expand access to quality treatment regimes in Kenya.

Following the signing of a joint Memorandum of Understanding (MoU) between NHIF and Johnson & Johnson Middle East FZ-LLC (Janssen Kenya), the prescription drug, Abiraterone Acetate used for the treatment of advanced prostate …